Clinical Trial

Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma

Study acronym: TARMAC
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open label, multi-center, single-arm, phase II study investigating the efficacy and safety of the combination of ibrutinib and Tisagenlecleucel in twenty patients with relapsed or refractory Mantle Cell Lymphoma (MCL) or who had sub-optimal response to standard therapy in the presence of TP53 mutation.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2020-01-15; most recent amendment 2024-11-06.
Status change: Recruiting → Active, Not Recruiting 2021-10-19
Status change: Not Yet Recruiting → Recruiting 2020-06-29
Trial Details
NCT Number NCT04234061
Lead Sponsor Peter MacCallum Cancer Centre, Australia
Collaborators: Novartis
Conditions Mantle Cell Lymphoma Recurrent
Enrollment 20 participants
Start Date 2020-04-07
Primary Completion 2027-09-01 (estimated)
Study Completion 2030-09-01 (estimated)
Updated on ClinicalTrials.gov 2024-11-07